Kiniksa Pharmaceuticals
KNSA
56 hedge funds and large institutions have $295M invested in Kiniksa Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 31 increasing their positions, 5 reducing their positions, and 5 closing their positions.
520% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 5
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
8.41% more ownership
Funds ownership: 79.15% → 87.56% (+8.4%)
8% more funds holding
Funds holding: 52 → 56 (+4)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
24% less capital invested
Capital invested by funds: $385M → $295M (-$90.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$31.1M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
+$11.2M |
| 3 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$8.63M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.53M |
| 5 |
BlackRock
New York
|
+$6.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$10.8M |
| 2 |
Millennium Management
New York
|
-$1.46M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$1.25M |
| 4 |
AG
Algert Global
San Francisco,
California
|
-$300K |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$247K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Legal & General Group
London,
United Kingdom
| $36K | +$19.5K | +1,010 | +103% |
|
|
AIP
52
Ameritas Investment Partners
Lincoln,
Nebraska
| $10K | – | – | – |
|
|
TRCT
53
Tower Research Capital (TRC)
New York
| $9K | +$9.62K | +498 | New |
|
|
CWA
54
Clarus Wealth Advisors
Peoria,
Arizona
| $4K | +$4.37K | +226 | New |
|
55
Daiwa Securities Group
Tokyo,
Japan
| $2K | +$2.26K | +117 | New |
|
56
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| $1K | +$1.06K | +55 | New |
|
|
57
Invesco
Atlanta,
Georgia
| – | -$1.25M | -44,363 | Closed |
|
|
AG
58
Algert Global
San Francisco,
California
| – | -$300K | -10,694 | Closed |
|
|
59
AllianceBernstein
Nashville,
Tennessee
| – | -$247K | -8,800 | Closed |
|
60
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$4K | -145 | Closed |
|
61
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$3K | -92 | Closed |
|
KNSA Hedge Fund Activity: Q1 2019 in Review
56 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q1 2019, worth a combined $295M — down 24% from $385M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new KNSA positions and 5 closed out — a net gain of 4 holders — while 31 added to existing stakes and 5 trimmed.
The largest buyer was ArrowMark Colorado Holdings, opening a new position worth an estimated $31.1M. The largest seller was Cormorant Asset Management, cutting an estimated $10.8M.
- 56 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q1 2019, up from 52 in Q4 2018.
- Funds reported $295M of Kiniksa Pharmaceuticals stock for Q1 2019, down 24% quarter-over-quarter.
- 9 funds opened new Kiniksa Pharmaceuticals positions in Q1 2019 and 5 closed out, a net change of +4 holders.
- The largest Kiniksa Pharmaceuticals buyer in Q1 2019 was ArrowMark Colorado Holdings, an estimated $31.1M added.
- The largest Kiniksa Pharmaceuticals seller in Q1 2019 was Cormorant Asset Management, an estimated $10.8M sold.
Based on aggregated 13F filings for Q1 2019.